Mutual Funds Sahi Hai!
To avail the service, you will be redirected to loans.geojitcredits.com
The company said the facility remains an important part of its global manufacturing and supply network, with continued focus on quality systems, regulatory compliance, and patient safety.
Granules India is primarily involved in the manufacturing and sale of active pharmaceutical ingredients (APIs), pharmaceutical formulation intermediates (PFIs), and finished dosages (FDs). The company’s consolidated net profit climbed 32.58% to Rs 201.56 crore on 22.81% increase in revenue from operations to Rs 1,470.60 crore in Q4 FY26 over Q4 FY25.
Divis Laboratories Ltd, Granules India Ltd, Mangalore Refinery And Petrochemicals Ltd, Alkyl Amines Chemicals Ltd are among the other stocks to see a surge in volumes on BSE today, 03 June 2026.
Concord Biotech Ltd witnessed volume of 1.68 lakh shares by 10:46 IST on BSE, a 9.35 times surge over two-week average daily volume of 17948 shares. The stock increased 6.13% to Rs.1,238.30. Volumes stood at 74467 shares in the last session.
Divis Laboratories Ltd saw volume of 1.78 lakh shares by 10:46 IST on BSE, a 7.15 fold spurt over two-week average daily volume of 24834 shares. The stock dropped 0.15% to Rs.6,518.50. Volumes stood at 16261 shares in the last session.
Granules India Ltd clocked volume of 5.05 lakh shares by 10:46 IST on BSE, a 4.59 times surge over two-week average daily volume of 1.10 lakh shares. The stock gained 1.71% to Rs.790.10. Volumes stood at 30974 shares in the last session.
Mangalore Refinery And Petrochemicals Ltd registered volume of 8.35 lakh shares by 10:46 IST on BSE, a 3.76 fold spurt over two-week average daily volume of 2.22 lakh shares. The stock rose 4.11% to Rs.153.25. Volumes stood at 1.53 lakh shares in the last session.
Alkyl Amines Chemicals Ltd witnessed volume of 48669 shares by 10:46 IST on BSE, a 3.25 times surge over two-week average daily volume of 14986 shares. The stock increased 1.11% to Rs.1,806.40. Volumes stood at 84431 shares in the last session.
Granules India Ltd, Usha Martin Ltd, JK Tyre & Industries Ltd, Exide Industries Ltd are among the other stocks to see a surge in volumes on NSE today, 27 May 2026.
AIA Engineering Ltd recorded volume of 9.88 lakh shares by 14:14 IST on NSE, a 19.58 times surge over two-week average daily volume of 50441 shares. The stock gained 6.00% to Rs.4,391.80. Volumes stood at 2.41 lakh shares in the last session.
Granules India Ltd saw volume of 106.42 lakh shares by 14:14 IST on NSE, a 15.18 fold spurt over two-week average daily volume of 7.01 lakh shares. The stock increased 4.03% to Rs.787.00. Volumes stood at 7.36 lakh shares in the last session.
Usha Martin Ltd recorded volume of 51.5 lakh shares by 14:14 IST on NSE, a 12.63 times surge over two-week average daily volume of 4.08 lakh shares. The stock gained 6.14% to Rs.510.30. Volumes stood at 5.17 lakh shares in the last session.
JK Tyre & Industries Ltd saw volume of 111.59 lakh shares by 14:14 IST on NSE, a 10 fold spurt over two-week average daily volume of 11.15 lakh shares. The stock increased 5.23% to Rs.414.75. Volumes stood at 15.73 lakh shares in the last session.
Exide Industries Ltd recorded volume of 212.15 lakh shares by 14:14 IST on NSE, a 8.93 times surge over two-week average daily volume of 23.75 lakh shares. The stock gained 7.52% to Rs.393.80. Volumes stood at 73.52 lakh shares in the last session.
For the full year,net profit rose 18.64% to Rs 595.02 crore in the year ended March 2026 as against Rs 501.52 crore during the previous year ended March 2025. Sales rose 19.81% to Rs 5338.92 crore in the year ended March 2026 as against Rs 4455.97 crore during the previous year ended March 2025.
EBITDA stood at Rs 352.1 crore in Q4 FY26, registering the growth of 40%, compared with Rs 252.4 crore in Q4 FY25.EBITDA margin improved to 24% in Q4 FY26 as against 21% in Q4 FY25.
Revenue from operations in Q4 FY26 was driven by finished dosages (FD) at 73%, followed by active pharmaceutical ingredients (API) at 13%, pharmaceutical formulation intermediates (PFI) at 9%, and peptide/CDMO at 5%.
On a full-year basis, the company’s consolidated net profit climbed 18.65% to Rs 595.02 crore on 19.73% increase in revenue from operations to Rs 5365.64 crore in FY26 over FY25.
Krishna Prasad Chigurupati, chairman & managing director of Granules India said, “We delivered a strong performance in Q4FY26, driven by continued portfolio expansion, disciplined execution, and steady progress across regulatory, compliance, and sustainability initiatives. The quarter reflects improving earnings quality and sustained advancement in Complex Generics and the Peptides CDMO platform.”
Granules India is primarily involved in the manufacturing and sale of active pharmaceutical ingredients (APIs), pharmaceutical formulation intermediates (PFIs), and finished dosages (FDs).